full report link
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif disclosur import disclosur pleas go www wolferesearch com/disclosur write
us wolf research llc lexington avenu suit new york ny
summari rate price target
multipl abbv/bmy/pf base pro forma estim
factset wolf research estim analysi price
companyratingpric pt multipl epsu/d price astrazeneca azn squibb nv novn vx opchf rhhbi rog vx ppchf sni sasi pa pp average average return vs wr global macro outlook
summari view group modestli attract base total sharehold return current valuat
posit side
 product slowli trend aggreg
growth outlook compani steadi mani instanc improv
emerg market contribut nice growth last driven mostli china
neg side
despit better still plenti compani whose pipelin thin spend
also mani big compani often chase smaller target opportun
us drug price remain spotlight presidenti elect inject uncertainti
respons challeng drug compani
cut cost match lower revenu
reli help fill gap
narrow focu divesting/spinning/swap asset
wolf research estim analysi
wr global major theme
clinic data alway import driver
first wave adjuv studi includ lung data azn/rog
novel moa rog tigit nsclc gsk ico bmi lli
alzheim dz could get credit deriv play biib aducanumab
bmy/celg durabl data celg liso-cel cancer psoriasi
headlin risk possibl smaller chang budget process execut order watersh
moment part low probabl import canadian drug propos
presidenti cycl promis keep drug price spotlight key uncertainti
remain skew toward smaller bolt-on sub big deal rare period happen
one impedi larger deal lack big target good fundament palat valuat
compani report wolf research analysi
wr global rel valuat return
global pharma trade discount
averag
global pharma big move
period under-perform
wolf research estim analysi price-to-earnings calcul base
base revenu analysi view differ view
window base revenu
window base revenu
growth profil across base revenu exclud futur pipelin drug
instruct see compani biggest futur loss fill
compani report wolf research estim analysi revenu adjust
reflect partner lynparza azn eliqui dupix san venclexta
imbruvica
compani report wolf research estim analysi
view view view reveneu growth ep growth ep growth reveneu growth ep growth revenu growth summari view
astrazeneca op best long-term ep grower must stock
gener well-lik seem short mostli given bear case extern weak cash flow
view must stock
pharmaco check mani box
high rel growth peer ep
durabl growth reflect new product launch cycl small/manag
pipelin option collect upsid downsid bc investor expect still mix
heavi exposur hot diseas area oncolog rev today
theoret take-out potenti smaller size rel big pharmaco tri
extern weak cash flow fairli stale bear case flow issu self-limit unless someth blow
tagrisso get approv china given question find subset flaura
china major growth driver could suddenli go wrong singl payer market
consensu model margin expans fast alway tough know
could ceo pascal soriot leav focu investor
treme variou combo
event daiichi-sankyo day dec talk
ye must stock best grower coverag
ye reason
wolf research estim analysi
bristol-my squibb op pipelin execut drive price-to-earnings multipl higher
stock work recent yet remain controversi larg out-of-favor due futur patent cliff
view reason clear path upsid next
recent clear event lung celg deal closur
bmi celg one fuller pipelin group lot news flow next
assum execut pipelin broadli modest price-to-earnings multipl expans occur
patent cliff still big ugli continu make us think one reason celg deal fend suitor
upsid point price-to-earnings multipl cap below-group-averag level bc patent cliff
right target price-to-earnings multipl big patent cliff compani use vs peer averag mid-teen
long-term trajectori opdivo mani variabl limit lung read-out
pipelin news full result updat data liso-cel ozanimod pdufa
guidanc mum much guidanc given updat otezla divestitur
revlimid patent challeng ipr tradit paragraph iv patent challeng on-going
ye perfect stretch valuat still low howev import understand
bet pipelin entail make seri bet binari event
less clear time tell burden proof show lt patent cliff manag
wolf research estim analysi
merck op depend keytruda nah yet least
gener well-lik mount concern high depend keytruda
keytruda fantast well year launch nearli doubl
market expans opportun three differ front investor exposur adjuv
usag gen agent synerg ex-u opportun under-model see report link
eventu keytruda problem loe draw closer advanc hmmm
fact driver growth gardasil link lynparza lenvima
averag ep growth durabl upward bia beat rais stori
price-to-earnings multipl slightli group averag
keytruda risk competitor adjuv read-out mrk novel moa could threaten shift market share
price-to-earnings multipl realli start discount keytruda loe
pipelin thin solut larger
ever get rid anim health dont hold breath appreci upsid decid divest
ye valuat still reason growth deliv continu beats/rais
wolf research estim analysi
novarti op anoth garpi namehop upsid
view stabl stori slowli execut wish lt growth better
good compani w/lot new product flow balanc across revenu stream
approv beovu mayzent zolgensma pipelin ofatumumab fevipipr inclisiran
price-to-earnings multipl bare group averag
unfortun long-term growth great sap new product strength
howev could get lift gilenya gener delay fevipipr real model yet
mdco
cosentyx co biggest growth driver categori grow price competit
fevipipr asthma exacerb trial hit
gilenya posit clariti whether gener delay vs street model
gilenya neg second deriv risk on-going tecfidera ipr
ofatumumab under-model rel rog ocrevu
zolgensma high dose come clinic hold
ye enough keep investor engag current valuat
ye esp given upsid possibl
wolf research estim analysi
pp agn reason solut low price-to-earnings high yield tantal
get bid deal announc get digest
deal confirm long said would occur larg transact
reason target thu upgrad under-perform peer perform announc made
high div yield low price-to-earnings suggest could drift even higher
howev still big humira exposur us humira alon pro-forma sale
blood cancer busi imbruvica/venclexta great ideal would go get solid tumor portfolio
catalyst-lit thin pipelin doesnt bring much tabl
roll-up roll-up pure financi engin finest right price-to-earnings multipl entiti like
rate us humira biosimilar eros still knowabl variabl includ interchang fda
skyrizi rinvoq jak bundl humira drive upsid
imbruvica risk next-gen btki seem manag
ftc risk chanc ftc could ask skyrizi divestitur would
reason idea base much stabl bought
wolf research estim analysi
pp seem stuck could get credit alzheim
sideway sinc april due competit threat hedg fund favorit short side
psycholog overhang like persist relat durabl growth driver mainli trulic taltz
lot ride tirzepatid news vacuum
alreadi given key guidanc element market choos believ
take dispel bear case probabl quarter financi result
worth watching/contempl lt model look robust howev price-to-earnings multipl still highest group
deriv play biib aducanumab alz dz outcom upsid like
diabet competit categori whop sale
insulin gener becom interchang mayb would mean faster eros
share loss new competitor rybelsu oral sema novo nordisk farxiga azn bc hf data
tirzepatid biolog gip well understood real-world toler high anti-drug antibodi
pipelin beyond tirzepatid thin offer free upsid
probabl remain sideway worth monitor
ye given lt growth profil matter entri point time
wolf research estim analysi
glaxosmithklin pp slowli block tackl
gradual appreci investor slow progress gsk make
lot chang better new manag tsro consum jv format eventu spin
pipelin compound still modest unless ico agonist hit
attract sotp use chc comp impli multipl pharma low given good durabl busi
ep growth like flattish respect
dividend yield bit better peer group averag
stock drift last hand month valuat approach peer group averag
balanc lt growth rate feel fairli valu
hiv competit well total gsk hiv portfolio still like remain fairli stabl
histor weak fixabl new head live far away balanc sheet constrain
shingrix great suppli limit could management sandbag regardless fixabl problem
pipelin read-out full bcma data daprodustat earli data tgf-b trap ico
also reason given durabl base main thrust would captur valu creation chc spin
wolf research estim analysi
pp better shape ex-upjohn expens level
underperform last year despit still hedg fund favorit short side
better shape ex-upjohn dispos leav remain smaller better growth profil
howev ex-upjohn basi price-to-earnings multipl high even adjust ownership newco
also ex-upjohn exposur key franchis prevnar ibranc downsid risk
pipelin get better still seem earli therefor difficult realist judg
stock would interest perhap low sotp say fair valu
enter repriev major start across
vyndaqel tafamidi enjoy strong initi start mayb big sourc lt upsid
prevnar pro-forma rev asymmetr downsid risk gain traction wolf prevnar prob ok
ibranc pro-forma rev asymmetr downsid risk adjuv trial dont hit wolf ibranc prob ok
data read-out abrocitinib jak atop derm ibranc adj trial late adult
event closur upjohn spin
opinion expens ex-upjohn easier see sourc downsid vs upsid
think better option moment
wolf research estim analysi
roch pp hard like good compani get credit alz dz
drift sentiment often skew posit pipelin
arguabl best compani coverag late-stag pipelin full
evidenc recent pipelin unplug conf call see link
howev simultan sit front end biosimilar exposur model uncertainti
model net show low singl digit lt ep compound-annual-growth-rate excit pipelin could outperform
continu monitor balanc gain loss net esp bc expens
deriv play biib acucanumab outcom upsid like
model us biosimilar eros start ramp avastin biosim share juli launch
pipelin big enough overcom biosimilar loss possibl
pipelin data serd sabc risdiplam approv etrolizumab ipataserib
read balovaptan late htt-aso file updat point
reason play pipelin option upsid
reason reason
wolf research estim analysi
sanofi pp hope trade go dec analyst meet
sentiment improv hope new manag shake thing
ep growth level slightli averag return due natur phase busi
dupix great like weather competit threat well
 weak late-stag pipelin thin good new head fix
lantus/toujeo often describ investor stabil collect sell eur annual
total san sale declin
valuat low usual like regard help put floor
new cfo automot industri track record cut cost final happen
san spin consum health possibl would in-lin pharmaco
dupix acceler due broader atop derm asthma roll-out
new indic could drive growth next humira
competit growth eg oral jak ad tezepelumab asthma
 seem highli like quickest way bolster pipelin last deal bioverativ good
upsid case reason current valuat yet need concret evid posit
perhap believ mean revers san histor creat lot valu
wolf research estim analysi
excl upjohn average excl pro forma azn w/o average europ healthcar compani comparison cover pharma pp peer peform under-perform op outperformsourc factset wolf researchtim anderson md target multipl disclosur
